PandemieGrippaleV1, PubMed, Corpus, bibRecord, 000893

Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Identifieur interne : 000893 ( PubMed/Corpus ); précédent : 000892; suivant : 000894

Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Auteurs : Bao-Zhong Wang ; Harvinder S. Gill ; Cheng He ; Changbo Ou ; Li Wang ; Ying-Chun Wang ; Hao Feng ; Han Zhang ; Mark R. Prausnitz ; Richard W. Compans

Source :

Journal of controlled release : official journal of the Controlled Release Society [ 1873-4995 ] ; 2014.

RBID : pubmed:24417966

English descriptors

KwdEn :
- Administration, Cutaneous, Animals, Cell Line, Dogs, Flagellin (administration & dosage), Flagellin (immunology), Immunity, Immunoglobulin G (blood), Immunoglobulin G (immunology), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (administration & dosage), Ligands, Madin Darby Canine Kidney Cells, Mice, Microinjections, Needles, Orthomyxoviridae Infections (blood), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (immunology), Toll-Like Receptor 5 (chemistry), Toll-Like Receptor 5 (immunology), Viral Matrix Proteins (administration & dosage), Viral Matrix Proteins (immunology).
MESH :
- chemical , administration & dosage : Flagellin, Influenza Vaccines, Recombinant Fusion Proteins, Viral Matrix Proteins.
- chemical , blood : Immunoglobulin G.
- chemical , chemistry : Toll-Like Receptor 5.
- chemical , immunology : Flagellin, Immunoglobulin G, Recombinant Fusion Proteins, Toll-Like Receptor 5, Viral Matrix Proteins.
- blood : Orthomyxoviridae Infections.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Orthomyxoviridae Infections.
- prevention & control : Orthomyxoviridae Infections.
- virology : Orthomyxoviridae Infections.
- Administration, Cutaneous, Animals, Cell Line, Dogs, Immunity, Ligands, Madin Darby Canine Kidney Cells, Mice, Microinjections, Needles.

Abstract

Influenza vaccines with broad cross-protection are urgently needed to prevent an emerging influenza pandemic. A fusion protein of the Toll-like receptor (TLR) 5-agonist domains from flagellin and multiple repeats of the conserved extracellular domain of the influenza matrix protein 2 (M2e) was constructed, purified and evaluated as such a vaccine. A painless vaccination method suitable for possible self-administration using coated microneedle arrays was investigated for skin-targeted delivery of the fusion protein in a mouse model. The results demonstrate that microneedle immunization induced strong humoral as well as mucosal antibody responses and conferred complete protection against homo- and heterosubtypic lethal virus challenges. Protective efficacy with microneedles was found to be significantly better than that seen with conventional intramuscular injection, and comparable to that observed with intranasal immunization. Because of its advantages for administration, safety and storage, microneedle delivery of M2e-flagellin fusion protein is a promising approach for an easy-to-administer universal influenza vaccine.

DOI: 10.1016/j.jconrel.2014.01.002
PubMed: 24417966

Links to Exploration step

pubmed:24417966

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.</title>
<author><name sortKey="Wang, Bao Zhong" sort="Wang, Bao Zhong" uniqKey="Wang B" first="Bao-Zhong" last="Wang">Bao-Zhong Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: bwang3@emory.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gill, Harvinder S" sort="Gill, Harvinder S" uniqKey="Gill H" first="Harvinder S" last="Gill">Harvinder S. Gill</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Cheng" sort="He, Cheng" uniqKey="He C" first="Cheng" last="He">Cheng He</name>
<affiliation><nlm:affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ou, Changbo" sort="Ou, Changbo" uniqKey="Ou C" first="Changbo" last="Ou">Changbo Ou</name>
<affiliation><nlm:affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Li" sort="Wang, Li" uniqKey="Wang L" first="Li" last="Wang">Li Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Ying Chun" sort="Wang, Ying Chun" uniqKey="Wang Y" first="Ying-Chun" last="Wang">Ying-Chun Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feng, Hao" sort="Feng, Hao" uniqKey="Feng H" first="Hao" last="Feng">Hao Feng</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Han" sort="Zhang, Han" uniqKey="Zhang H" first="Han" last="Zhang">Han Zhang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name>
<affiliation><nlm:affiliation>School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: rcompan@emory.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24417966</idno>
<idno type="pmid">24417966</idno>
<idno type="doi">10.1016/j.jconrel.2014.01.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000893</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000893</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.</title>
<author><name sortKey="Wang, Bao Zhong" sort="Wang, Bao Zhong" uniqKey="Wang B" first="Bao-Zhong" last="Wang">Bao-Zhong Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: bwang3@emory.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gill, Harvinder S" sort="Gill, Harvinder S" uniqKey="Gill H" first="Harvinder S" last="Gill">Harvinder S. Gill</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Cheng" sort="He, Cheng" uniqKey="He C" first="Cheng" last="He">Cheng He</name>
<affiliation><nlm:affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ou, Changbo" sort="Ou, Changbo" uniqKey="Ou C" first="Changbo" last="Ou">Changbo Ou</name>
<affiliation><nlm:affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Li" sort="Wang, Li" uniqKey="Wang L" first="Li" last="Wang">Li Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Ying Chun" sort="Wang, Ying Chun" uniqKey="Wang Y" first="Ying-Chun" last="Wang">Ying-Chun Wang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feng, Hao" sort="Feng, Hao" uniqKey="Feng H" first="Hao" last="Feng">Hao Feng</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Han" sort="Zhang, Han" uniqKey="Zhang H" first="Han" last="Zhang">Han Zhang</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name>
<affiliation><nlm:affiliation>School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: rcompan@emory.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of controlled release : official journal of the Controlled Release Society</title>
<idno type="eISSN">1873-4995</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Flagellin (administration & dosage)</term>
<term>Flagellin (immunology)</term>
<term>Immunity</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Ligands</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Mice</term>
<term>Microinjections</term>
<term>Needles</term>
<term>Orthomyxoviridae Infections (blood)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Recombinant Fusion Proteins (administration & dosage)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Toll-Like Receptor 5 (chemistry)</term>
<term>Toll-Like Receptor 5 (immunology)</term>
<term>Viral Matrix Proteins (administration & dosage)</term>
<term>Viral Matrix Proteins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Flagellin</term>
<term>Influenza Vaccines</term>
<term>Recombinant Fusion Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Toll-Like Receptor 5</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Flagellin</term>
<term>Immunoglobulin G</term>
<term>Recombinant Fusion Proteins</term>
<term>Toll-Like Receptor 5</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Immunity</term>
<term>Ligands</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Mice</term>
<term>Microinjections</term>
<term>Needles</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza vaccines with broad cross-protection are urgently needed to prevent an emerging influenza pandemic. A fusion protein of the Toll-like receptor (TLR) 5-agonist domains from flagellin and multiple repeats of the conserved extracellular domain of the influenza matrix protein 2 (M2e) was constructed, purified and evaluated as such a vaccine. A painless vaccination method suitable for possible self-administration using coated microneedle arrays was investigated for skin-targeted delivery of the fusion protein in a mouse model. The results demonstrate that microneedle immunization induced strong humoral as well as mucosal antibody responses and conferred complete protection against homo- and heterosubtypic lethal virus challenges. Protective efficacy with microneedles was found to be significantly better than that seen with conventional intramuscular injection, and comparable to that observed with intranasal immunization. Because of its advantages for administration, safety and storage, microneedle delivery of M2e-flagellin fusion protein is a promising approach for an easy-to-administer universal influenza vaccine. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24417966</PMID>
<DateCompleted><Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<PubDate><Year>2014</Year>
<Month>Mar</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Journal of controlled release : official journal of the Controlled Release Society</Title>
<ISOAbbreviation>J Control Release</ISOAbbreviation>
</Journal>
<ArticleTitle>Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.</ArticleTitle>
<Pagination><MedlinePgn>1-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2014.01.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0168-3659(14)00019-4</ELocationID>
<Abstract><AbstractText>Influenza vaccines with broad cross-protection are urgently needed to prevent an emerging influenza pandemic. A fusion protein of the Toll-like receptor (TLR) 5-agonist domains from flagellin and multiple repeats of the conserved extracellular domain of the influenza matrix protein 2 (M2e) was constructed, purified and evaluated as such a vaccine. A painless vaccination method suitable for possible self-administration using coated microneedle arrays was investigated for skin-targeted delivery of the fusion protein in a mouse model. The results demonstrate that microneedle immunization induced strong humoral as well as mucosal antibody responses and conferred complete protection against homo- and heterosubtypic lethal virus challenges. Protective efficacy with microneedles was found to be significantly better than that seen with conventional intramuscular injection, and comparable to that observed with intranasal immunization. Because of its advantages for administration, safety and storage, microneedle delivery of M2e-flagellin fusion protein is a promising approach for an easy-to-administer universal influenza vaccine. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Bao-Zhong</ForeName>
<Initials>BZ</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: bwang3@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gill</LastName>
<ForeName>Harvinder S</ForeName>
<Initials>HS</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ou</LastName>
<ForeName>Changbo</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Ying-Chun</ForeName>
<Initials>YC</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Han</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prausnitz</LastName>
<ForeName>Mark R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Compans</LastName>
<ForeName>Richard W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: rcompan@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01EB006369</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AI101047</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AI068003</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI101047</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI068003</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>01</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Control Release</MedlineTA>
<NlmUniqueID>8607908</NlmUniqueID>
<ISSNLinking>0168-3659</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488937">M2 protein, Influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051198">Toll-Like Receptor 5</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>12777-81-0</RegistryNumber>
<NameOfSubstance UI="D005408">Flagellin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005408" MajorTopicYN="N">Flagellin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008845" MajorTopicYN="N">Microinjections</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009339" MajorTopicYN="N">Needles</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051198" MajorTopicYN="N">Toll-Like Receptor 5</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cross-protection</Keyword>
<Keyword MajorTopicYN="N">Influenza M2e</Keyword>
<Keyword MajorTopicYN="N">Microneedle array</Keyword>
<Keyword MajorTopicYN="N">TLR5 ligand</Keyword>
<Keyword MajorTopicYN="N">Universal influenza vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>07</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>01</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24417966</ArticleId>
<ArticleId IdType="pii">S0168-3659(14)00019-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.jconrel.2014.01.002</ArticleId>
<ArticleId IdType="pmc">PMC3951682</ArticleId>
<ArticleId IdType="mid">NIHMS555595</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ann Intern Med. 2003 Apr 1;138(7):608; author reply 608-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12667038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Phys Chem Solids. 2008 May;69(5-6):1537-1541</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20648232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2008 Aug 1;181(3):2036-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18641341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Aug 13;22(23-24):2993-3003</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15297047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2012;3(2):e00012-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22396479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2007 Feb 12;117(2):227-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17169459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Res. 2005;33(1):83-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16120974</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7968-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19416832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Aug;16(8):915-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20639891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2011 Apr;18(4):647-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21288996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2012 Jul 20;161(2):645-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22342643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 May 16;368(20):1888-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23577628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2012 Oct 28;163(2):230-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22921518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2013 Apr;7(2):64-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23612075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin J Pain. 2008 Sep;24(7):585-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18716497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2011 Jan;28(1):95-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20238152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(1):e14538</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21267073</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Nov 1;165(9):4778-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11045998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Deliv. 2012 Mar;3(3):357-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22833995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Apr;81(7):3514-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17251294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Immunol. 2008 May;45(9):2499-507</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18289677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Apr 16;30(18):2908-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22342501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1990 Mar;64(3):1375-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2304147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2009 Apr;8(4):499-508</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19348565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 May 28;28(24):4103-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19654062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2286-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15525713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2012 Aug;19(8):1119-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22647270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2000 Dec 5;278(1):55-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11112481</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2012 Nov;64(14):1547-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22575858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2007 Jul;24(7):1369-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17385011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2010 Nov 1;147(3):326-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20692307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(3):e4773</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19274084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Jun 2;21(19-20):2616-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12744898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2008 Apr 25;283(17):11382-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 25;26(27-28):3395-403</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18511159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1991 Mar 15;146(6):1750-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1826010</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2003 Dec;4(12):1247-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14625549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behring Inst Mitt. 1997 Feb;(98):33-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9382757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(4):e10266</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20422002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2011;2(1):e00328-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21325038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2011 Jun 30;152(3):349-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21371510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Jan 15;186(2):1022-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21169548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 Aug;62(8):2762-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2455818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2007 Apr;14(4):375-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17329444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Jan 14;27(3):454-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19022318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(11):e13972</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21124769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1995 Oct 1;212(2):411-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7571410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2011 Jan;28(1):135-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20387097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1993 Jan;74 ( Pt 1):143-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8423445</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Dec;82(23):11813-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18786995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):757-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21187388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jan 10;26(2):201-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18063235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Apr;12(4):569-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16704803</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000893 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000893 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24417966
   |texte=   Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24417966" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki